CUR-004

About Curatis

Curatis is a Swiss public biotech focused on developing innovative therapeutics for rare diseases and oncology. Its core asset is a proprietary technology platform designed to identify novel targets and generate optimized drug candidates. The company's strategy centers on advancing its clinical-stage programs, CUR-001 and CUR-002, through proof-of-concept while expanding its preclinical pipeline. With a modest market valuation, Curatis represents a high-risk, high-reward investment opportunity in the specialized European biotech sector.

Therapeutic Areas